Navigation Links
Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argos's Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
Date:5/3/2012

DURHAM, N.C., May 3, 2012 /PRNewswire/ -- Argos Therapeutics Inc. today announced that study results demonstrated that analytical treatment interruption to assess the antiviral activity of Argos's Arcelis™ personalized immunotherapy for the treatment of HIV patients, AGS-004, is an acceptable strategy for at least 16 weeks. Study results were published in the Journal of Medical Virology (84:885–889, 2012).

"Establishing the safety of analytical treatment interruptions of at least 16 weeks is an important step forward in assessing the impact of immunotherapy on viral load control," said Charles Nicolette, Ph.D., chief scientific officer and vice president of research and development of Argos. "Therapeutic vaccines such as AGS-004 have the potential to decrease long-term antiretroviral therapy which has limitations such as drug toxicity, the risk of developing resistance and others. We look forward to advancing our Phase 2b trial of AGS-004 to further demonstrate its efficacy and safety for the treatment of HIV patients."

The potential risks of short-term interruption of antiretroviral therapy in the AGS-004-001 study were assessed in a retrospective subgroup study analyzing data from patients in the strategies for management of anti-retroviral therapy (SMART) study with matched eligibility criteria. The subgroup analysis included 440 of 2,720 on the drug conservation (DC) arm and 436 of 2,752 on the viral suppression (VS) arm that matched the AGS-004-001 inclusion criteria and were used in the SMART subgroup analysis. In the first 16 weeks following randomization into the SMART study there were no deaths in either subgroup.  There were two AIDS-related events in the DC subgroup and one in the VS subgroup, making the overall risk of AIDS related events two per 100 person years (0.005%) and one per 100 person years (0.002%) in the two subgroups, respectively.  There were
'/>"/>

SOURCE Argos Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... 2015 A drug commonly taken to prevent seizures ... multiple sclerosis (MS), according to a study released today that ... Annual Meeting in Washington, DC , April ... people with MS experience at some point in their life ... carrying vision from the eye to the brain gets inflamed," ...
(Date:4/16/2015)...  Amgen (NASDAQ: AMGN ) today announced that ... Tuesday, April 21, 2015, after the close of the ... a conference call with the investment community at 2 ... be Robert A. Bradway , chairman and chief ... team. Live audio of the conference call ...
(Date:4/16/2015)... , April 16, 2015  Diplomat Pharmacy, Inc. ... Shannon Beltrand to their senior leadership team as ... be responsible for securing and properly monitoring Diplomat,s data, ... both internally and externally. Additionally, she will play key ... "We are very excited to have someone ...
Breaking Medicine Technology:Epilepsy Drug May Preserve Eyesight for People with MS 2Amgen Announces Webcast Of 2015 First Quarter Financial Results 2Diplomat Names Shannon M. Beltrand as New CISO 2
... TEMECULA, Calif., Nov. 17 Patient Safety Technologies, Inc. ... results. , "We are continuing to see strong year ... margins," stated Steven H. Kane, Chief Executive Officer of ... sales of safety sponges were comparable with revenues in ...
... WebMD Health Corp. (Nasdaq: WBMD ) today announced that executives ... Research Small and Mid Cap Conference on Friday, November 20, 2009 ... general public are invited to listen to a live audio broadcast ... accessed at www.wbmd.com (in the Investor Relations ...
Cached Medicine Technology:Patient Safety Technologies Reports Third Quarter Results 2Patient Safety Technologies Reports Third Quarter Results 3Patient Safety Technologies Reports Third Quarter Results 4Patient Safety Technologies Reports Third Quarter Results 5Patient Safety Technologies Reports Third Quarter Results 6
(Date:4/17/2015)... Washington, DC (PRWEB) April 17, 2015 ... the HHT Diagnoses and Treatment Act HR 1849 in ... improve diagnosis rates and treatment for patients with the ... introduced in the past, would be the first to ... diagnoses and appropriate treatment of hereditary hemorrhagic telangiectasia. This ...
(Date:4/17/2015)... As a board-certified orthopedic surgeon, Dr. ... of platelet-rich plasma (PRP) and stem cell ... known for its world-class care of injury-caused and chronic ... lacking in many other physicians offering regenerative medicines. ... for pain management and rehabilitation. Dr. Meier and MOSM ...
(Date:4/17/2015)... Tallahassee, Fla. (PRWEB) April 17, 2015 ... percent of dental restoration units are made overseas by ... Commission. Additionally, domestic labs remain unregulated in more than ... , The National Association of Dental Laboratories ... campaign to raise awareness among patients about the consequences ...
(Date:4/17/2015)... Jacksonville, Fla. (PRWEB) April 17, 2015 ... Cancer Center have signed a partnership agreement designed to ... , The institutions have agreed to create a ... Anderson’s treatment protocols and translational research. Baptist MD Anderson ... of 2015, providing a single destination for highly coordinated, ...
(Date:4/17/2015)... April 17, 2015 Scientists from ... multicenter team of U.S. and Venezuelan researchers, have ... in humans among an isolated tribe of Yanomami ... Bacterial diversity in the Yanomami, previously unexposed to ... nearly double that of people living in industrialized ...
Breaking Medicine News(10 mins):Health News:House Representatives Introduce Bill to Fight Genetic Disease 2Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 2Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 3Health News:National Association Urges Transparency in Dental Industry 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 3Health News:Mount Sinai Scientists Find Unprecedented Microbial Diversity in Isolated Amazonian Tribe Previously Unexposed to Antibiotics or Processed Foods 2Health News:Mount Sinai Scientists Find Unprecedented Microbial Diversity in Isolated Amazonian Tribe Previously Unexposed to Antibiotics or Processed Foods 3
... Fat Pad Restoration on The Balancing Act on Lifetime TelevisionBOCA ... great doing it" is more than a tag line for ... is a leading expert and innovator in the science of ... a woman, she understands the emotional needs that many women ...
... Pharmakon introduced next generation of health ... quality natural liquid calcium & mineral supplement ... segments of athletes, women in pre and ... calcium supplementation. The innovative products of Aim ...
... the HR outsourcing marketplace, Empyrean Benefit Solutions is changing the status ... lower price. , ... Houston, TX (PRWEB) January 12, ... to grow by over 800% in annual revenue in their first ...
... employ comparative effectiveness research tools to address large, unwarranted variations ... benefits corporate spending. , ... Phoenixville, ... effectiveness data addresses large and unwarranted variations in corporate spending. ...
... SAN FRANCISCO, Jan. 12 Hiemstra Product Development, ... the debut of,hiQual, its proprietary electronic quality management ... the integration of hiQual, Hiemstra,s development team can ... the necessary documentation,required under ISO 13485:2003 and FDA ...
... Jan. 12 Acclarent, Inc., a leading,medical technology ... address conditions affecting the ear, nose and,throat, announced ... financing round.,Acclarent intends to use the proceeds to ... as on-going investment in product,development and clinical studies. ...
Cached Medicine News:Health News:Kay Renz Steps into PR Position for Cosmetic Foot, Leg and Vein Doctor, Jodi Schoenhaus 2Health News:AIM Pharmakon Introduced Next Generation of Health and Longevity Products with a Unique Premium Quality Natural Liquid Calcium & Mineral Supplement Concentrate 2Health News:AIM Pharmakon Introduced Next Generation of Health and Longevity Products with a Unique Premium Quality Natural Liquid Calcium & Mineral Supplement Concentrate 3Health News:AIM Pharmakon Introduced Next Generation of Health and Longevity Products with a Unique Premium Quality Natural Liquid Calcium & Mineral Supplement Concentrate 4Health News:Empyrean Benefit Solutions, Inc. Surpasses HRO Market's Expectations 2Health News:Empyrean Benefit Solutions, Inc. Surpasses HRO Market's Expectations 3Health News:Comparative Effectiveness Research Tools Address Variations in corporate spending 2Health News:Comparative Effectiveness Research Tools Address Variations in corporate spending 3Health News:Reduce Risk, Achieve Compliance and Accelerate Time to Market with hiQual and Hiemstra Product Development 2Health News:Acclarent, Inc. Closes $26 Million Financing 2
Attachments: Clip bar for tubes 10 to 19 mm in diameter Overall Dimension Height IC: 6 (15.2) Overall Dimension Length IC: 18.5 (46.9) Overall Dimension Width IC: 4 (10.2)...
... The Vibratome Roto-Shake Genie is an ... It performs five different mixing ... and rotating/rolling, as well as a ... The precision-engineered moving portion of the ...
... The Vibratome Roto-Shake Genie is ... platform. It performs five different ... rolling/rocking and rotating/rolling, as well as ... The precision-engineered moving portion of ...
The model 55D Rocking Shaker provides the same Reliable quality as the 55S, but double the value. The 55D gives you an additional platform with a height of 3.25 in....
Medicine Products: